MYXOID LIPOSARCOMA
Clinical trials for MYXOID LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new MYXOID LIPOSARCOMA trials appear
Sign up with your email to follow new studies for MYXOID LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to revive failing cancer fighters in rare sarcomas
Disease control Recruiting nowThis early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatmen…
Matched conditions: MYXOID LIPOSARCOMA
Phase: EARLY_PHASE1 • Sponsor: Seth Pollack • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThis study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental virus vaccine takes on multiple cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Last-Resort cell therapy offered to sarcoma patients
Disease control AVAILABLEThis expanded access program offers a cell therapy called afamitresgene autoleucel (afami-cel) to people with synovial sarcoma or myxoid liposarcoma whose manufactured dose didn't meet commercial standards. Eligible patients have no other feasible treatment options. The therapy i…
Matched conditions: MYXOID LIPOSARCOMA
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC